Previously unrecognized behavioral phenotype in Gaucher disease type 3
- PMID: 28634598
- PMCID: PMC5458667
- DOI: 10.1212/NXG.0000000000000158
Previously unrecognized behavioral phenotype in Gaucher disease type 3
Abstract
Objective: To provide a comprehensive description of abnormal behaviors in patients with Gaucher disease type 3 (GD3) and relate these behaviors to demographic, neurodevelopmental, and neurologic characteristics.
Methods: Thirty-four Egyptian patients with GD3 (mean age of 7.9 years) were enrolled in the study. They were selected based on parent report and/or physician observation of one or more abnormal behaviors documented in 2 settings and by 2 different individuals and/or by video recording. Behaviors were grouped into 4 categories: Crying/Withdrawal, Impatience/Overactivity, Anger/Aggression, and Repetitive Acts. Baseline and follow-up 6-12 monthly neurologic evaluations included IQ assessment and an EEG. All patients were receiving enzyme replacement therapy (30-60 IU/kg every 2 weeks) and were followed for periods of 3-10 years.
Results: Supranuclear palsy of horizontal gaze, and of both horizontal and vertical gaze, bulbar symptoms, seizures, convergent strabismus, abnormal gait, and neck retroflexion were present in 97.1%, 50%, 55.9%, 29.4%, 29.4%, 20.6%, and 4.4% of patients, respectively. The most abnormal behavioral features were excessive anger (88.2%) and aggression (64.7%), and both were significantly higher in males. Anger/Aggression scores were highly correlated with IQ but not with either EEG/Seizure status or neurologic signs.
Conclusions: We describe behavioral problems with a unique pattern of excessive anger and aggression in patients with GD3. Defining these components using quantitative behavioral scoring methods holds promise to provide a marker of neurologic disease progression and severity.
Figures
Similar articles
-
Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt.Neurol Genet. 2016 Feb 25;2(2):e55. doi: 10.1212/NXG.0000000000000055. eCollection 2016 Apr. Neurol Genet. 2016. PMID: 27123474 Free PMC article.
-
A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades.Orphanet J Rare Dis. 2019 Nov 14;14(1):257. doi: 10.1186/s13023-019-1244-9. Orphanet J Rare Dis. 2019. PMID: 31727115 Free PMC article.
-
Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients.Blood Cells Mol Dis. 2018 Feb;68:86-92. doi: 10.1016/j.bcmd.2016.10.011. Epub 2016 Oct 21. Blood Cells Mol Dis. 2018. PMID: 27789132
-
The role of neurogenetics in Gaucher disease.Arch Neurol. 1993 Nov;50(11):1212-24. doi: 10.1001/archneur.1993.00540110088009. Arch Neurol. 1993. PMID: 8215980 Review.
-
Behavioral Interventions for Anger, Irritability, and Aggression in Children and Adolescents.J Child Adolesc Psychopharmacol. 2016 Feb;26(1):58-64. doi: 10.1089/cap.2015.0120. Epub 2016 Jan 8. J Child Adolesc Psychopharmacol. 2016. PMID: 26745682 Free PMC article. Review.
Cited by
-
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease.PLoS One. 2020 Jan 13;15(1):e0227077. doi: 10.1371/journal.pone.0227077. eCollection 2020. PLoS One. 2020. PMID: 31929594 Free PMC article.
-
A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.Acta Neurol Belg. 2024 Aug;124(4):1213-1223. doi: 10.1007/s13760-024-02493-1. Epub 2024 Feb 28. Acta Neurol Belg. 2024. PMID: 38413480 Review.
-
Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy.Elife. 2022 Aug 16;11:e79830. doi: 10.7554/eLife.79830. Elife. 2022. PMID: 35972072 Free PMC article.
-
Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.Mol Genet Metab. 2021 Feb;132(2):49-58. doi: 10.1016/j.ymgme.2021.01.002. Epub 2021 Jan 9. Mol Genet Metab. 2021. PMID: 33483255 Free PMC article. Review.
-
The definition of neuronopathic Gaucher disease.J Inherit Metab Dis. 2020 Sep;43(5):1056-1059. doi: 10.1002/jimd.12235. Epub 2020 Apr 3. J Inherit Metab Dis. 2020. PMID: 32242941 Free PMC article.
References
-
- Abdelwahab M, Blankenship D, Schiffmann R. Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt. Neurol Genet 2016;2:e55 doi: 10.1212/NXG.0000000000000055. - DOI - PMC - PubMed
-
- Erikson A, Bembi B, Schiffmann R. Neuronopathic forms of Gaucher's disease. Baillieres Clin Haematol 1997;10:711–723. - PubMed
-
- Campbell PE, Harris CM, Vellodi A. Deterioration of the auditory brainstem response in children with type 3 Gaucher disease. Neurology 2004;63:385–387. - PubMed
-
- Altarescu G, Hill S, Wiggs E, et al. . The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001;138:539–547. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources